 NEW YORK, June 1, 2021 PRNewswire -- Pomerantz LLP announces that a class action lawsuit has been filed against FibroGen, Inc. FibroGen or the Company NASDAQ: FGEN and certain of its officers. The class action, filed in the United States District Court for the Northern District of California, and docketed under 21-cv-03212, is on behalf of a class consisting of all persons and entities other than Defendants who purchased or otherwise acquired FibroGen securities andor sold put options from November 8, 2019, through and including April 6, 2021 the Class Period, seeking to recover damages pursuant to Sections 10b and 20a of the Securities Exchange Act of 1934 the Exchange Act, 15 U.S.C. 